Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines

Giulio Stefanini80 enrolled

Overview

As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised. So far, the evidence supporting pharmacological preventive strategies in cardio-oncology has been inconsistent and conflicting, and there is a clear need for well-designed trials with novel interventions. In this study, by using cardiac magnetic resonance, the investigators want to assess if a commonly used beta-blocker with a unique pharmacological profile, i.e. nebivolol, can prevent cardiac dysfunction in patients with breast cancer or diffuse large B-cell lymphoma undergoing chemotherapy with anthracyclines.

During the last decades, major efforts have been made in the field of cancer therapy to improve prognosis and quality of life of patients treated with any sort of chemotherapy. Cardiotoxicity represents one of the most relevant adverse effects of chemotherapy, primarily in patients treated with anthracyclines. The potential protective role of cardiovascular medications in the prevention of cardiotoxicity associated with anthracyclines chemotherapy is still a matter of debate since evidence in this field are scarce and largely inconclusive. Indeed, prior studies were often limited by a non-blinded design or an echocardiography-based assessment of left ventricular ejection fraction (with a relevant inter and intra-operator variability). The primary objective of the trial is to evaluate the cardioprotective effects of the betablocker nebivolol in an individually randomized, parallel, placebo-controlled, double-blinded (patient, treating physician, investigator, outcomes assessor, statistician), superiority trial in patients with a solid tumor (i.e., breast cancer) or a hematologic malignancy (i.e., diffuse large B cell lymphoma) who have a normal cardiac function as assessed by echocardiography and will receive anthracyclines as part of their first-line chemotherapy program. Indeed, recent evidence suggests that anthracycline cardiotoxicity seems mainly due to an anthracycline-induced dysregulation of mitochondrial activity and metabolism in cardiomyocytes. Nebivolol has a distinctive profile among beta-blockers, with the unique power of increasing the nitric oxide bioavailability. Nebivolol-induced nitric oxide release has shown favourable effects in terms of antioxidant activity, cardiac neo-angiogenesis, mitochondrial and endothelial protection. On this basis, the individually randomized, parallel, placebo-controlled, double-blinded (patient, treating physician, investigator, outcomes assessor, statistician), superiority CONTROL trial will assess the cardioprotective effects of a commonly used betablocker (nebivolol) in patients with baseline normal left ventricular systolic function receiving anthracycline chemotherapy as first-line chemotherapy for breast cancer or diffuse large B-cell lymphoma. The assessment of left ventricular ejection fraction and related endpoints will be performed with cardiac magnetic resonance.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years * Established histologic diagnosis of breast cancer or diffuse large B-cell lymphoma * Planned chemotherapy with anthracyclines * left ventricular ejection fraction ≥55% (assessed by echocardiography) * Ability to provide informed consent Exclusion Criteria: * Known intolerance/contraindications to betablocker therapy * History of coronary artery disease * History of cardiomyopathy * History of heart failure * Ongoing treatment with betablockers for other indications * Heart rate at baseline \<60 beats per minute * Arterial blood pressure at baseline \<100/60 mmHg * Contraindications to undergo cardiac magnetic resonance (e.g., non-compatible pacemakers or metallic prosthesis) * Pregnancy or lactation * Current participation to another study

Outcomes

Primary Outcomes

Left Ventricular Ejection Fraction reduction assessed by Cardiac Magnetic Resonance

The primary endpoint is defined as Left Ventricular Ejection Fraction (LVEF) reduction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12 months of follow-up. LVEF reduction is defined as the difference between LVEF at baseline and LVEF at 12 months follow-up (LVEF reduction = Baseline LVEF - 12 months LVEF).

Time frame: from baseline to 12 months

Secondary Outcomes

Left ventricular ejection fraction assessed by Cardiac Magnetic Resonance

Left ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12-month follow-up.

Time frame: at 12-month follow-up

Myocardial fibrosis assessed by Cardiac Magnetic Resonance

Myocardial fibrosis assessed by Cardiac Magnetic Resonance with T1-mapping sequences and with Late Gadolinium Enhancement images.

Time frame: at 12-month follow-up

Myocardial edema assessed by Cardiac Magnetic Resonance

Myocardial edema assessed by Cardiac Magnetic Resonance with T2 sequences.

Time frame: at 12-month follow-up

Right ventricular ejection fraction assessed by Cardiac Magnetic Resonance

Right ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance

Time frame: at 12-month follow-up

Left ventricular end-diastolic volume assessed by Cardiac Magnetic Resonance

Left ventricular end-diastolic volume (unit of measurement: ml) assessed by Cardiac Magnetic Resonance